JNJ vs AVDL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AVDL Captures Institutional Edge (3โ1 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avadel Pharmaceuticals plc Ordinary Share (AVDL) driven by superior Valuation, Momentum & Technical, Options & Structure while JNJ counters with relative strength in Growth & Margin. Fundamentally, JNJ trades at 23.3x Forward P/E with 26.6% operating margin (+5.9% YoY revenue) versus AVDL at 28.8x Forward P/E and 2.5% operating margin (+54.9% YoY). In options structure, JNJ sits in CONSOLIDATION (45th %ile IV; Dealer Gamma Walls on Pro) against AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | JNJ | AVDL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $643.1B | $2.1B | Larger Scale | JNJ |
| Trailing P/E Ratio Valuation | 40.5x | 16.8x | Lower Multiple | AVDL |
| Forward P/E Ratio Valuation | 23.3x | 28.8x | Lower Multiple | JNJ |
| Revenue Growth (YoY) Growth | +5.9% | +54.9% | Higher Growth | AVDL |
| Operating Margin (TTM) Profitability | 26.6% | 2.5% | Higher Margin | JNJ |
| Net Profit Margin Profitability | 16.2% | -0.1% | Higher Margin | JNJ |
| Return on Equity (ROE) Capital Efficiency | 20.0% | -0.3% | Higher ROE | JNJ |
| 52-Week Range Position Momentum | 78% ($199โ$290) | 89% ($6โ$24) | Stronger Trend | AVDL |
| Beta / 30D Volatility Risk Regime | -0.04ฮฒ ยท 25% Vol | 0.14ฮฒ ยท 2% Vol | Lower Realized Risk | AVDL |
| Unified Institutional Score Composite Signal | 57.8 / 100 (HOLD) | 62.9 / 100 (BUY) | Higher Composite | AVDL |